BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 18, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

April 30, 2010

View Archived Issues

Clinical data from the evaluation of Debio-025 in HCV-infected patients disclosed

Read More

Recent data support safety and potentcy of HCV NS3 protease inhibitor ACH-1625

Read More

Positive modulators of nAChRalpha7 identified at NeuroSearch

Read More

Roche claims novel gamma-secretase inhibitors

Read More

Snapshots: new reports on biomarkers related to cardiovascular disorders

Read More

Novel tachykinin NK3 receptor antagonists identified at Roche

Read More

Tibotek discloses novel CYP450 inhibitors as boosters for anti-HIV agents

Read More

Novel protein kinase inhibitors presented by Priaxon

Read More

Secreted phospholipase A2 a potential marker of traumatic brain injury

Read More

Intraprostatic botulinum toxin type A improves signs and symptoms of BPH

Read More

Padeliporfin-mediated vascular targeted phototherapy promising in prostate cancer trial

Read More

REDUCE study clarifies effects of dutasteride in prostate cancer

Read More

First quarter events at Chugai

Read More

VaxInnate presents preliminary results from phase II study of VAX-125 flu vaccine

Read More

FDA approves once-daily dosing of Kaletra for previously treated HIV patients

Read More

Prana releases position statement on PBT-2 therapeutic strategy in Alzheimer's disease

Read More

Tarceva receives E.U. approval as maintenance treatment in advanced NSCLC

Read More

Takeda submits NDA for azilsartan medoxomil to treat hypertension in the U.S.

Read More

New biotechnology company, Immunovo, secures seed funding

Read More

New company LipimetiX created to focus on lipid-lowering treatments

Read More

FDA issues complete response letter for Giazo NDA

Read More

PolyMedix initiates phase Ib/II dose-ranging PMX-60056 study

Read More

Ceregene starts new phase I/II study of CERE-120 for Parkinson's disease

Read More

Johns Hopkins and the New York Stem Cell Foundation to collaborate on stem cell research

Read More

Dendreon receives FDA approval for Provenge for castrate-resistant prostate cancer

Read More

NexMed's NexACT technology improves delivery and activity of Angstrom's A6 anticancer compound

Read More

Hana Biosciences completes pre-NDA meeting with FDA for Marqibo

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 18, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • GLP-1 capsule

    Maintenance, man: Lilly’s phase III weight trial hits goals

    BioWorld
    Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
  • Insilico CEO Alex Zhavoronkov and the automated lab’s humanoid that runs all preclinical tests in the Hong Kong lab.

    AI drug developer Insilico to raise $292 million in Hong Kong IPO

    BioWorld
    Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing